Cencora, Inc.

NYSE:COR Stock Report

Market Cap: US$47.1b

Cencora Valuation

Is COR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: COR ($240.24) is trading below our estimate of fair value ($642.9)

Significantly Below Fair Value: COR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COR?

Key metric: As COR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for COR. This is calculated by dividing COR's market cap by their current earnings.
What is COR's PE Ratio?
PE Ratio31.2x
EarningsUS$1.51b
Market CapUS$47.09b

Price to Earnings Ratio vs Peers

How does COR's PE Ratio compare to its peers?

The above table shows the PE ratio for COR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.6x
CAH Cardinal Health
22.5x7.7%US$28.7b
MCK McKesson
30.3x15.0%US$77.0b
HSIC Henry Schein
27.3x26.7%US$8.6b
PDCO Patterson Companies
10.3x8.4%US$1.7b
COR Cencora
31.2x14.6%US$47.1b

Price-To-Earnings vs Peers: COR is expensive based on its Price-To-Earnings Ratio (31.2x) compared to the peer average (22.6x).

Price to Earnings Ratio vs Industry

How does COR's PE Ratio compare vs other companies in the US Healthcare Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NEUE NeueHealth
1.5xn/aUS$41.24m
IDXG Interpace Biosciences
2.6xn/aUS$12.54m
FZMD Fuse Medical
1.1xn/aUS$4.22m
No more companies available in this PE range
COR 31.2xIndustry Avg. 25.1xNo. of Companies12PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: COR is expensive based on its Price-To-Earnings Ratio (31.2x) compared to the US Healthcare industry average (25.1x).

Price to Earnings Ratio vs Fair Ratio

What is COR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.2x
Fair PE Ratio34.1x

Price-To-Earnings vs Fair Ratio: COR is good value based on its Price-To-Earnings Ratio (31.2x) compared to the estimated Fair Price-To-Earnings Ratio (34.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$240.24
US$267.20
+11.2%
7.8%US$292.00US$230.00n/a16
Nov ’25US$234.27
US$257.32
+9.8%
7.6%US$287.00US$215.00n/a16
Oct ’25US$224.23
US$259.92
+15.9%
7.5%US$287.00US$215.00n/a16
Sep ’25US$239.57
US$262.05
+9.4%
7.5%US$287.00US$215.00n/a16
Aug ’25US$244.46
US$260.98
+6.8%
7.7%US$287.00US$215.00n/a16
Jul ’25US$223.53
US$255.98
+14.5%
9.0%US$280.00US$194.00n/a16
Jun ’25US$226.57
US$255.33
+12.7%
9.3%US$280.00US$194.00n/a15
May ’25US$229.20
US$254.84
+11.2%
8.6%US$280.00US$194.00n/a16
Apr ’25US$243.00
US$247.84
+2.0%
10.4%US$270.00US$183.00n/a16
Mar ’25US$237.03
US$247.00
+4.2%
10.7%US$270.00US$183.00n/a15
Feb ’25US$236.92
US$234.73
-0.9%
12.6%US$267.00US$183.00n/a15
Jan ’25US$205.38
US$211.71
+3.1%
6.7%US$235.00US$176.00n/a14
Dec ’24US$204.09
US$208.92
+2.4%
6.3%US$223.00US$176.00n/a13
Nov ’24US$187.23
US$207.23
+10.7%
8.4%US$225.00US$162.00US$234.2713
Oct ’24US$179.97
US$206.23
+14.6%
8.1%US$225.00US$162.00US$224.2313
Sep ’24US$174.96
US$206.36
+17.9%
7.9%US$225.00US$162.00US$239.5714
Aug ’24US$189.10
US$194.79
+3.0%
8.9%US$213.00US$149.00US$244.4614
Jul ’24US$192.43
US$187.13
-2.8%
8.1%US$208.00US$149.00US$223.5315
Jun ’24US$172.59
US$186.20
+7.9%
7.6%US$207.00US$149.00US$226.5715
May ’24US$166.79
US$181.47
+8.8%
7.1%US$205.00US$149.00US$229.2015
Apr ’24US$160.11
US$181.20
+13.2%
6.9%US$201.00US$149.00US$243.0015
Mar ’24US$156.51
US$181.62
+16.0%
7.2%US$201.00US$149.00US$237.0313
Feb ’24US$161.05
US$181.17
+12.5%
7.9%US$201.00US$149.00US$236.9212
Jan ’24US$165.71
US$176.82
+6.7%
7.0%US$195.00US$148.00US$205.3811
Dec ’23US$171.63
US$177.45
+3.4%
6.2%US$195.00US$155.00US$204.0911
Nov ’23US$156.32
US$172.50
+10.4%
6.4%US$191.00US$155.00US$187.2312

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Lantheus Holdings

US$5.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$76.83

7D

-12.2%

1Y

12.7%

Patterson Companies

US$1.7b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

PDCO

US$19.75

7D

-5.0%

1Y

-38.3%

Enhabit

US$369.6m

Provides home health and hospice services in the United States.

EHAB

US$7.35

7D

-6.8%

1Y

-25.2%